作者：
Haijiao,Zhang [1]
;
Samantha,Savage [1]
;
Anna Reister,Schultz [1]
;
Daniel,Bottomly [2]
;
Libbey,White [2]
;
Erik,Segerdell [2]
;
Beth,Wilmot [2]
;
Shannon K,McWeeney [2]
;
Christopher A,Eide [3]
;
Tamilla,Nechiporuk [1]
;
Amy,Carlos [4]
;
Rachel,Henson [4]
;
Chenwei,Lin [4]
;
Robert,Searles [4]
;
Hoang,Ho [5]
;
Yee Ling,Lam [5]
;
Richard,Sweat [5]
;
Courtney,Follit [5]
;
Vinay,Jain [5]
;
Evan,Lind [6]
;
Gautam,Borthakur [7]
;
Guillermo,Garcia-Manero [7]
;
Farhad,Ravandi [7]
;
Hagop M,Kantarjian [7]
;
Jorge,Cortes [7]
;
Robert,Collins [8]
;
Daelynn R,Buelow [9]
;
Sharyn D,Baker [9]
;
Brian J,Druker [3]
;
Jeffrey W,Tyner [10]
作者单位：
Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University Knight Cancer Institute, Portland, 97239, OR, USA.;Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, 97239, OR, USA.
[1]
Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute, Portland, 97239, OR, USA.
[2]
Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, 97239, OR, USA.;Howard Hughes Medical Institute, Portland, 97239, OR, USA.
[3]
Integrated Genomics, Knight Cancer Institute, Oregon Health & Science University Knight Cancer Institute, Portland, 97239, OR, USA.
[4]
AROG Pharmaceuticals, Dallas, 75240, TX, USA.
[5]
Molecular Microbiology & Immunology, Oregon Health & Science University Knight Cancer Institute, Portland, 97239, OR, USA.
[6]
The University of Texas MD Anderson Cancer Center, Houston, 77030, TX, USA.
[7]
University of Texas Southwestern Medical Center, Dallas, 75390, TX, USA.
[8]
The Ohio State University College of Pharmacy and Comprehensive Cancer Center, Columbus, 43210, OH, USA.
[9]
Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University Knight Cancer Institute, Portland, 97239, OR, USA. tynerj@ohsu.edu.;Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, 97239, OR, USA. tynerj@ohsu.edu.
[10]
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);动物(Animals);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);苯咪唑类(Benzimidazoles);细胞系, 肿瘤(Cell Line, Tumor);抗药性, 肿瘤(Drug Resistance, Neoplasm);药物筛选试验, 抗肿瘤(Drug Screening Assays, Antitumor);后成说, 遗传(Epigenesis, Genetic);女(雌)性(Female);GTP磷酸水解酶类(GTP Phosphohydrolases);HEK293细胞(HEK293 Cells);人类(Humans);半数抑制浓度(Inhibitory Concentration 50);异柠檬酸脱氢酶(Isocitrate Dehydrogenase);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);男(雄)性(Male);膜蛋白质类(Membrane Proteins);小鼠(Mice);中年人(Middle Aged);突变(Mutation);哌啶类(Piperidines);蛋白激酶抑制剂(Protein Kinase Inhibitors);吡啶酮类(Pyridones);嘧啶酮类(Pyrimidinones);串联重复序列(Tandem Repeat Sequences);治疗结果(Treatment Outcome);fms样酪氨酸激酶3(fms-Like Tyrosine Kinase 3)
DOI
10.1038/s41467-018-08263-x
PMID
30651561
发布时间
2024-11-14
换一批
换一批
